Industry News/Funding

Theradigm Technology as AIDS Treatment To Be Developed

Published in Cancer Weekly, September 25th, 1995

Cytel Corporation, San Diego, California, announced that it has been awarded a Strategic Programs for Innovative Research on AIDS Treatment (SPIRAT) grant from the U.S. National Institutes of Health (NIH) to conduct research on the development of its Theradigm technology as a peptide-based immunotherapeutic vaccine for HIV-1 infection.

The SPIRAT grant, totaling $3.3 million over a four year period, is awarded by the NIH through the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The award period commenced September 1, 1995. The grant will fund a multi-project program, to include human clinical trials, aimed at developing an immunotherapeutic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-09-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry